On November 24, 2022, Ahead Biocomputing Co. Ltd. and Mescue-Janusys Inc. (headquartered in Chuo-ku, Tokyo and led by President & CEO Koichiro Kitamura) announced that they had signed a Memorandum of Understanding (MOU) for collaboration in peptide drug discovery using a hybrid design system that combines computational and experimental methods to improve efficiency in middle molecule drug discovery.
Mescue-Janusys Inc.
https://www.mescuejanusys.com/
